| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ya-Hsuan Wang, Chia-Yu Liu, Yu-Ning Her, Hung-Hsi Wu, Chia-Yi Yao, Tien-Yu Che. Lurasidone Successfully Reversed Clozapine-Induced Type 2 Diabetes Mellitus and Hypertriglyceridemia in a Patient With Schizophrenia. American journal of therapeutics. 2023-02-02. PMID:36731051. |
lurasidone successfully reversed clozapine-induced type 2 diabetes mellitus and hypertriglyceridemia in a patient with schizophrenia. |
2023-02-02 |
2023-08-14 |
Not clear |
| María Elena Gamboa-Arancibia, Nelson Caro, Alexander Gamboa, Javier Octavio Morales, Jorge Enrique González Casanova, Diana Marcela Rojas Gómez, Sebastián Miranda-Roja. Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin. Pharmaceutics. vol 15. issue 1. 2023-01-21. PMID:36678861. |
this is the case of lurasidone hydrochloride-a drug used for the treatment of schizophrenia and bipolar depression. |
2023-01-21 |
2023-08-14 |
Not clear |
| Andrea Fagiolini, Miriam Olivola, Lisa Lavatelli, Antonello Bellomo, Caterina Lobaccaro, Nathalie Falsetto, Marco Micillo, Alessandro Cuom. Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice. Annals of general psychiatry. vol 21. issue 1. 2022-12-16. PMID:36527022. |
treatment persistence in patients with schizophrenia treated with lurasidone in italian clinical practice. |
2022-12-16 |
2023-08-14 |
Not clear |
| Andrea Fagiolini, Miriam Olivola, Lisa Lavatelli, Antonello Bellomo, Caterina Lobaccaro, Nathalie Falsetto, Marco Micillo, Alessandro Cuom. Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice. Annals of general psychiatry. vol 21. issue 1. 2022-12-16. PMID:36527022. |
this study evaluated treatment persistence to lurasidone (lur) in patients with schizophrenia in a real-world italian setting. |
2022-12-16 |
2023-08-14 |
Not clear |
| Valerio Ricci, Giovanni Martinotti, Domenico De Berardis, Giuseppe Main. Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report. International journal of environmental research and public health. vol 19. issue 23. 2022-12-11. PMID:36498129. |
lurasidone is an atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia. |
2022-12-11 |
2023-08-14 |
Not clear |
| Jia Liu, Lidan Cao, Jing W. Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Frontiers in public health. vol 10. 2022-11-28. PMID:36438279. |
corrigendum: cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in china. |
2022-11-28 |
2023-08-14 |
Not clear |
| Andrea Fiorillo, Alessandro Cuomo, Gaia Sampogna, Umberto Albert, Paola Calò, Giancarlo Cerveri, Sergio De Filippis, Gabriele Masi, Maurizio Pompili, Gianluca Serafini, Antonio Vita, Alessandro Zuddas, Andrea Fagiolin. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert opinion on pharmacotherapy. vol 23. issue 16. 2022-11-18. PMID:36398838. |
lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. |
2022-11-18 |
2023-08-14 |
Not clear |
| Andrea Fiorillo, Alessandro Cuomo, Gaia Sampogna, Umberto Albert, Paola Calò, Giancarlo Cerveri, Sergio De Filippis, Gabriele Masi, Maurizio Pompili, Gianluca Serafini, Antonio Vita, Alessandro Zuddas, Andrea Fagiolin. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert opinion on pharmacotherapy. vol 23. issue 16. 2022-11-18. PMID:36398838. |
lurasidone is an atypical antipsychotic agent approved in the european union for the treatment of schizophrenia in adults and adolescents (13-17 years). |
2022-11-18 |
2023-08-14 |
Not clear |
| Itaru Miura, Kei Watabe, Reiko Sakaguchi, Keisuke Okamoto, Hidenori Maruyam. Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study. Neuropsychiatric disease and treatment. vol 18. 2022-11-17. PMID:36387943. |
effectiveness of lurasidone 80 mg in patients with schizophrenia: results of an open-label, 12-week extension study. |
2022-11-17 |
2023-08-14 |
Not clear |
| Itaru Miura, Kei Watabe, Reiko Sakaguchi, Keisuke Okamoto, Hidenori Maruyam. Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study. Neuropsychiatric disease and treatment. vol 18. 2022-11-17. PMID:36387943. |
to evaluate the effectiveness and safety of lurasidone 80 mg/day (versus the 40 mg/day dose) during a 12-week, open-label extension study in patients with an acute exacerbation of schizophrenia who had completed a 6-week double-blind study of lurasidone. |
2022-11-17 |
2023-08-14 |
Not clear |
| Jia Liu, Lidan Cao, Jing W. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Frontiers in public health. vol 10. 2022-10-03. PMID:36187655. |
cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in china. |
2022-10-03 |
2023-08-14 |
Not clear |
| Jia Liu, Lidan Cao, Jing W. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China. Frontiers in public health. vol 10. 2022-10-03. PMID:36187655. |
to evaluate the cost-effectiveness of lurasidone compared with olanzapine and risperidone in the first-line treatment of patients with schizophrenia from a chinese healthcare system perspective. |
2022-10-03 |
2023-08-14 |
Not clear |
| Jolanta Orzelska-Górka, Joanna Mikulska, Anna Wiszniewska, Grażyna Biał. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International journal of molecular sciences. vol 23. issue 18. 2022-09-23. PMID:36142523. |
the purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. |
2022-09-23 |
2023-08-14 |
Not clear |
| Amy Dymond, Daniela Afonso, Will Gree. Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom. BMC health services research. vol 22. issue 1. 2022-08-24. PMID:36002828. |
cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the united kingdom. |
2022-08-24 |
2023-08-14 |
Not clear |
| Amy Dymond, Daniela Afonso, Will Gree. Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom. BMC health services research. vol 22. issue 1. 2022-08-24. PMID:36002828. |
lurasidone, a second-generation atypical antipsychotic, represents an additional treatment option alongside existing antipsychotics for adolescents and adults with schizophrenia. |
2022-08-24 |
2023-08-14 |
Not clear |
| Angaja Phalguni, Rachael McCool, Hannah Wood, Alice Sanderson, Gustaf Rydevik, Brooke Franklin, Daniel Jame. Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia. International clinical psychopharmacology. 2022-08-02. PMID:35916575. |
systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia. |
2022-08-02 |
2023-08-14 |
Not clear |
| Angaja Phalguni, Rachael McCool, Hannah Wood, Alice Sanderson, Gustaf Rydevik, Brooke Franklin, Daniel Jame. Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia. International clinical psychopharmacology. 2022-08-02. PMID:35916575. |
a systematic review was undertaken to identify randomized controlled trials (rcts) comparing the efficacy and safety of lurasidone, brexpiprazole and cariprazine (selected because of a shared safety profile) with each other or placebo in adult patients with schizophrenia. |
2022-08-02 |
2023-08-14 |
Not clear |
| Karsten Gjessing Jense. Severe Hyperprolactinemia during Lurasidone Treatment in a 16-year Old Girl with Schizophrenia - A Case Report. Scandinavian journal of child and adolescent psychiatry and psychology. vol 10. issue 1. 2022-07-29. PMID:35903553. |
severe hyperprolactinemia during lurasidone treatment in a 16-year old girl with schizophrenia - a case report. |
2022-07-29 |
2023-08-14 |
Not clear |
| Kathy Cheng Wang, Qiaohong Guo, Zijian Kuang, Jianyang Jin, Dan Li, Wenbin Chen, Wenquan Zhu, Min L. Structural elucidation of two novel degradants of lurasidone and their formation mechanisms under free radical-mediated oxidative and photolytic conditions via liquid chromatography-photodiode array/ultraviolet-tandem mass spectrometry and one-dimensional/two-dimensional nuclear magnetic resonance spectroscopy. Journal of mass spectrometry : JMS. vol 57. issue 7. 2022-06-23. PMID:35739062. |
lurasidone is an antipsychotic drug clinically used for the treatment of schizophrenia and bipolar disorder. |
2022-06-23 |
2023-08-14 |
Not clear |
| Taro Kishi, Hiroshi Nakamura, Nakao Iwat. Early Improvement as a Predictor of Later Response to Lurasidone in Schizophrenia from Japan Trials: A Diagnostic Test. Psychiatry and clinical neurosciences. 2022-05-19. PMID:35588424. |
early improvement as a predictor of later response to lurasidone in schizophrenia from japan trials: a diagnostic test. |
2022-05-19 |
2023-08-13 |
Not clear |